Dr. Oz has extolled Ozempic’s promise for weight-loss. Now Medicare, which Trump wants Oz to oversee, may cover it.

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' ...

Investors were excited as U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Former Wisconsin Rep. Mike Gallagher joined 'America's Newsroom' to discuss Trump's tariff threat against China and his ...

Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, ...

Delving into the details, we found 12% of traders were bullish, while 75% showed bearish tendencies. Out of all the trades we ...

Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a ...